Completed
PHASE4
INTERVENTIONAL
NCT02137538
Aromatase Inhibitor Growth Study: Letrozole vs. Anastrozole
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The purpose of the study is to determine if there are differences in the final height or hormone profile of short pubertal boys placed on different forms of aromatase inhibitor now routinely used to increase stature: Anastrozole and Letrozole. It also should determine if there are differences in the side effect profiles of the two drugs to be used.
Interventions
Name:
Letrozole
Type:
DRUG
Description:
Name:
Anastrozole
Type:
DRUG
Description:
Primary Outcomes
Measure:
Predicted Adult Height at Year 3
TimeFrame:
Year 3
Description:
Heights will be obtained by physical exam every 6 months during treatment. Skeletal maturation will be assessed from an x-ray by the method of Greulich and Pyle at baseline and every 12 months until the end of treatment.
Predicted adult height will be calculated at baseline and at the end of treatment based upon measured height and skeletal maturation (bone age).
Trial Information
NCT ID
NCT02137538
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE4
Sponsor
Stanford University
Last Updated
December 15, 2025